Multiple Myeloma: all 3,712 studies
Page 31 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.
- Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological MalignanciesCompletedNCT01204164Phase 1
- Study of CX-4945 in Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT01199718Phase 1
- Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantActive, not recruitingNCT01199562
- Study to Investigate Adherence of Patients to Clodronate (Bonefos) TreatmentCompletedNCT01198457
- Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus PrednisoneCompletedNCT01190787Phase 2
- Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC)CompletedNCT01186224Not applicable
- Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple MyelomaCompletedNCT01183949Phase 1/2
- Total Skeletal Irradiation in Multiple Myeloma Before Second Autologous Hematopoietic Stem Cell TransplantationTerminatedNCT01182233Phase 1
- Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related DisordersActive, not recruitingNCT01177527
- High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
- Vertebral Augmentation With Kyphoplasty vs Nonsurgical Mgmt for Vertebral Body Compression FracturesWithdrawnNCT01175278Not applicable
- The Pathophysiology of Bortezomib Induced Peripheral NeuropathyStatus unknownNCT01171443
- "WB-DCE-MRI" in Multiple Myeloma as an Independent Prognostic Factor for Disease-free SurvivalCompletedNCT01171430Not applicable
- Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple MyelomaCompletedNCT01168804Phase 2
- Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to LenalidomideCompletedNCT01166113Phase 1/2
- Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic CancerCompletedNCT01164709Phase 1
- Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple MyelomaCompletedNCT01163357Phase 1
- Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma PatientsCompletedNCT01160107Phase 2
- A Safety and Tolerability Study of PCI-24781 in Subjects With CancerCompletedNCT01149668Phase 1
- Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple MyelomaCompletedNCT01148108Phase 2
- A Study of AT9283 in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01145989Phase 2
- Blood Samples to Identify Biomarkers in Haploidentical Graft RecipientsCompletedNCT01141959
- Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure StudyCompletedNCT01139476
- B-Receptor Signaling in CardiomyopathyCompletedNCT01135849
- VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)Status unknownNCT01134484Phase 3
- Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving ChemotherapyCompletedNCT01132833
- AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or LymphomaCompletedNCT01129193Phase 1
- Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor DiseaseWithdrawnNCT01125449Phase 2
- A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple MyelomaCompletedNCT01122875Phase 1
- Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma PatientsTerminatedNCT01121120Phase 2
- Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom MacroglobulinemiaCompletedNCT01118689Phase 1
- Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma PatientsTerminatedNCT01116128Phase 2
- Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MMCompletedNCT01114282Phase 1
- Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)Status unknownNCT01114048Phase 2
- Prevention of Left Ventricular Dysfunction During ChemotherapyCompletedNCT01110824Phase 3
- Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)TerminatedNCT01109407
- Exploratory Study on POL6326 in Stem Cell MobilizationCompletedNCT01105403Phase 2
- A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple MyelomaTerminatedNCT01101594Phase 1/2
- Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With MalignanciesWithdrawnNCT01101412Phase 1/2
- Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving ChemotherapyTerminatedNCT01100879Phase 4
- Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma PatientsCompletedNCT01093196Phase 3
- Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple MyelomaCompletedNCT01091883Not applicable
- Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma SubjectsCompletedNCT01091831Phase 3
- Combination of Lenalidomide and Dexamethasone in Treatment of Multiple MyelomaCompletedNCT01090089Phase 3
- Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical RelapseCompletedNCT01087008Phase 4
- Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose TherapyCompletedNCT01085058Phase 2/3
- Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal FailureCompletedNCT01084837Phase 2
- Connect® MM- The Multiple Myeloma Disease RegistryTerminatedNCT01081028
- Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM.TerminatedNCT01079429
- Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell TransplantTerminatedNCT01077440
- Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple MyelomaCompletedNCT01074060Phase 1
- Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.CompletedNCT01070862Phase 3
- Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell TransplantationCompletedNCT01067287Phase 2
- Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma PatientsCompletedNCT01063179Phase 3
- Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early BortezomibCompletedNCT01060202
- Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal TranslocationCompletedNCT01058434Phase 2
- S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaWithdrawnNCT01055301Phase 2
- IFM2009-02-Pomalidomide and Dexamethasone Phase 2 MyelomaCompletedNCT01053949Phase 2
- Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerCompletedNCT01053494Not applicable
- Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple MyelomaCompletedNCT01045681Phase 2
- MSC and HSC Coinfusion in Mismatched MinitransplantsTerminatedNCT01045382Phase 2
- Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell CollectionStatus unknownNCT01042717Not applicable
- Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple MyelomaCompletedNCT01042704Phase 1
- Expanded Natural Killer (NK) Cells for Multiple Myeloma StudyCompletedNCT01040026Phase 1/2
- TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple MyelomaCompletedNCT01039025Phase 2
- A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01038388Phase 1
- Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell MobilizationCompletedNCT01037517Phase 2
- A Retreatment Study With Bortezomib for Multiple MyelomaCompletedNCT01030302
- Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients.CompletedNCT01026701
- A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple MyelomaCompletedNCT01025206Phase 1
- Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent TherapyTerminatedNCT01023880Phase 1/2
- Quality of Life in Multiple Myeloma Patients Treated With BortezomibCompletedNCT01021592
- Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT01019174Phase 1/2
- Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma SubjectsTerminatedNCT01018927
- Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on ChemotherapyCompletedNCT01016548Phase 3
- Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma PatientsCompletedNCT01010880Phase 1/2
- Third-line Therapy of Multiple Myeloma a Prospective Phase I /II TrialStatus unknownNCT01010243Phase 1/2
- Health-Related Quality of Life (QOL), Physical and Respiratory Function in Patients With Myeloma Affecting the SpineCompletedNCT01006070
- Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS)CompletedNCT01005628
- Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT01002703Phase 1/2
- Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma PatientsTerminatedNCT01002248Phase 3
- UARK 2009-32 Compassionate Use Study of CarfilzomibNo longer availableNCT00999414
- Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple MyelomaStatus unknownNCT00998270Phase 2/3
- Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple MyelomaCompletedNCT00996957Phase 1
- Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body IrradiationTerminatedNCT00996359Phase 1
- Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple MyelomaWithdrawnNCT00995059Phase 1/2
- Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With DapsoneCompletedNCT00993694
- IMGN901 in Combination With Lenalidomide and DexamethasoneCompletedNCT00991562Phase 1
- Dendritic Cells(DC)-Based Id Vaccination in Stage-I MyelomaCompletedNCT00988312Phase 1
- Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma PatientsTerminatedNCT00984828Phase 2/3
- Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood DisordersTerminatedNCT00973804Phase 1
- Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple MyelomaCompletedNCT00972712Phase 1
- Agaricus Blazei Murill in Patients With Multiple MyelomaCompletedNCT00970021Phase 2
- Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell GraftsWithdrawnNCT00968396Phase 2
- SCRI Tissue Testing RegistryTerminatedNCT00965861
- Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and MyelomaCompletedNCT00965224Phase 2
- Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell TransplantCompletedNCT00964821
- Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological MalignancyTerminatedNCT00963495Phase 1
- Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaCompletedNCT00962507Phase 1
- RMPT for Relapsed/Refractory Multiple MyelomaCompletedNCT00961467Phase 2